Antiviral vaccines with improved cellular immunogenicity
The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.
1. A nucleic acid molecule encoding a polypeptide comprising a sequence at least 99% identical to SEQ ID NO:12.
2. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes a polypeptide comprising the sequence of SEQ ID NO:12.
3. A vector comprising the nucleic acid molecule of claim 1 .
4. A vector comprising the nucleic acid molecule of claim 2 .
5. The vector of claim 3 , wherein said vector is an adenoviral vector or a pox virus vector.
6. The vector of claim 4 , wherein said vector is an adenoviral vector or a pox virus vector.
7. The vector of claim 5 , wherein said vector is selected from the group consisting of adenovirus serotype 26 (Ad26), adenovirus serotype 34 (Ad34), adenovirus serotype 35 (Ad35), adenovirus serotype 48 (Ad48), and adenovirus serotype 5 HVR48 (Ad5HVR48).
8. The vector of claim 5 , wherein said vector is Ad26.
9. The vector of claim 6 , wherein said vector is Ad26.
10. The vector of claim 5 , wherein said vector is a modified vaccinia virus Ankara (MVA).
11. The vector of claim 6 , wherein said vector is MVA.
12. A pharmaceutical composition comprising the vector of claim 3 and a pharmaceutically acceptable carrier, excipient, or diluent.
13. A pharmaceutical composition comprising the vector of claim 4 and a pharmaceutically acceptable carrier, excipient, or diluent.
14. The pharmaceutical composition of claim 12 , wherein said vector is an adenoviral vector or a pox virus vector.
15. The pharmaceutical composition of claim 13 , wherein said vector is an adenoviral vector or a pox virus vector.
16. The pharmaceutical composition of claim 14 , wherein said vector is Ad26.
17. The pharmaceutical composition of claim 15 , wherein said vector is Ad26.
18. The pharmaceutical composition of claim 14 , wherein said vector is MVA.
19. The pharmaceutical composition of claim 15 , wherein said vector is MVA.
20. A method for inducing an HIV-1 specific immune response in a mammal comprising administering to said mammal the nucleic acid of claim 1 or a vector comprising said nucleic acid.
21. A method for inducing an HIV-1 specific immune response in a mammal comprising administering to said mammal the nucleic acid of claim 2 or a vector comprising said nucleic acid.
22. The method of claim 20 , wherein said nucleic acid or said vector is in a pharmaceutical composition.
23. The method of claim 22 , wherein said vector is Ad26.
24. The method of claim 22 , wherein said vector is MVA.
25. The method of claim 20 , wherein said mammal is a human.
26. A kit comprising:
a) the pharmaceutical composition of claim 12 ;
b) instructions for use thereof; and, optionally,
c) an adjuvant.
27. A nucleic acid molecule encoding a polypeptide comprising a sequence at least 99% identical to SEQ ID NO:10, or a nucleic acid molecule encoding a polypeptide comprising the sequence of SEQ ID NO:13.